Workflow
SureSmile
icon
Search documents
DENTSPLY SIRONA(XRAY) - 2025 Q2 - Earnings Call Transcript
2025-08-07 13:32
Financial Data and Key Metrics Changes - Global sales for Q2 were $936 million, a decrease of 5% as reported or a negative 7% on a constant currency basis, with adjusted EBITDA margin at 21%, increasing 360 basis points year-over-year [13][20][21] - Adjusted earnings per share were $0.52, growing 7% compared to the prior year, driven primarily by active cost reduction programs [14][21] - Cash flow from operations was $48 million for the quarter, with a net debt to EBITDA ratio of 3.1 times [22][21] Business Line Data and Key Metrics Changes - EDS (Endo, Resto, and preventative products) saw a constant currency sales increase of 1.1%, while OIS (Orthodontic and Implant Solutions) sales declined 19.4% due to lower lab volumes globally [23][24] - CTS (Connected Technology Solutions) sales fell 5.9% in constant currency, with double-digit growth in imaging in Europe offset by declines in CADCAM and imaging in the U.S. [24] - Wellspect Healthcare sales declined 2.5%, impacted by prior year dealer stocking orders [25] Market Data and Key Metrics Changes - U.S. sales in Q2 were $293 million, down 18% in total or 11% excluding the BiTE impact, primarily due to softness in connected technology solutions and orthodontic and implant solutions [15] - European sales were approximately flat year-over-year, with Germany showing growth driven by CTS and SureSmile, which was up over 27% [16] - Rest of world sales were $239 million, up slightly year-over-year, with growth in essential dental solutions and SureSmile [16] Company Strategy and Development Direction - The company aims to enhance customer experience and support through simplified interactions and increased strategic investments [11][12] - Focus on innovation and speed to market is emphasized, with the DS Core platform gaining traction among users [11][12] - The company plans to streamline operations to unlock value and reduce costs, redirecting funds into sustained profitable growth [12][27] Management's Comments on Operating Environment and Future Outlook - Management noted that global patient volumes and procedures remained largely unchanged, with a focus on long-term strategies rather than short-term fluctuations [31][32] - The company maintains its full-year 2025 outlook for sales, adjusted EBITDA margin, and adjusted EPS despite current challenges [25][27] - Management is cautious about the impact of tariffs, with an updated annualized impact now estimated at $80 million [48][49] Other Important Information - A non-cash after-tax charge of approximately $214 million was recorded related to the impairment of goodwill and other intangible assets [21] - The company completed a $550 million hybrid bond offering in Q2, enhancing financial flexibility [22] Q&A Session Summary Question: Overview of the broader dental market - Management indicated that patient volumes remain stable, but procedural utilization in elective areas like implants and ortho continues to be soft, with a focus on long-term strategies [30][31] Question: Distributor stock dynamics - Management noted no significant revenue impact from distributor stock changes, with healthy positions in imaging and CADCAM [34][35] Question: Motivation for joining Dentsply - The new CEO expressed a desire to apply operational experience and execution strategies learned from previous roles to enhance Dentsply's performance [38][39] Question: Performance of implants - Management highlighted a decline in premium implants due to shifts from legacy brands, with expectations for growth driven by sales force changes and new consumer experiences [41][44] Question: Tariff assumptions - The annualized impact of tariffs has increased to about $80 million, with ongoing efforts to mitigate costs through supply chain efficiencies [47][48] Question: Adjustments on BiTE - A $4 million adjustment was noted for BiTE in Q2, with no further changes anticipated for the second half of the year [51] Question: Portfolio assessment and growth strategy - Management believes there are no major gaps in the portfolio, focusing on organic growth while remaining open to opportunistic acquisitions [56][58] Question: Confidence in value implants - Management acknowledged challenges in the value implant segment due to Middle East volatility but expects performance to improve in the second half of the year [88][89]
DENTSPLY SIRONA(XRAY) - 2025 Q2 - Earnings Call Transcript
2025-08-07 13:30
Financial Data and Key Metrics Changes - Global sales for Q2 were $936 million, a decrease of 5% as reported or a negative 7% on a constant currency basis, with adjusted EBITDA margin at 21%, increasing 360 basis points year-over-year [12][20] - Adjusted earnings per share were $0.52, growing 7% compared to the prior year, driven primarily by active cost reduction programs [12][20] - Cash flow from operations was $48 million for the quarter, a decline from $28 million in the prior year quarter [21] Business Line Data and Key Metrics Changes - EDS (Endo, Resto, and preventative products) sales increased 1.1% on a constant currency basis, with growth in the rest of the world, but lower volumes in Europe and the US [22] - OIS (Orthodontic and Implant Solutions) sales declined 19.4% in constant currency, with BiTE accounting for over half of the decline [22] - CTS (Connected Technology Solutions) sales fell 5.9% in constant currency, with double-digit growth in imaging in Europe offset by declines in CADCAM and imaging in the US [22] Market Data and Key Metrics Changes - US sales in Q2 were $293 million, down 18% in total or 11% excluding the BiTE impact, primarily driven by softness in connected technology solutions and orthodontic and implant solutions [14] - European sales were approximately $400 million, flat compared to Q2 of the prior year, with Germany showing growth driven by CTS and SureSmile, which was up over 27% [15] - Rest of world sales were $239 million, slightly up versus the prior year, with growth in essential dental solutions and SureSmile up double digits [15] Company Strategy and Development Direction - The company aims to enhance customer experience and support through simplified interactions and increased strategic investments [10] - Focus on innovation and speed to market, with a goal to shape the future of markets by partnering with practitioners [10] - The DS Core platform is a critical element of the strategy, with 50,000 unique users and increasing connected devices and lab orders processed [10] Management's Comments on Operating Environment and Future Outlook - Management noted that global patient volumes and procedures remained largely unchanged, with a focus on long-term strategies rather than short-term market fluctuations [32] - The company is maintaining its full-year 2025 outlook for sales, adjusted EBITDA margin, and adjusted EPS despite current challenges [26] - Management emphasized the importance of focusing on customer needs and improving execution to drive growth [95] Other Important Information - The company recorded a non-cash after-tax charge of approximately $214 million related to the impairment of goodwill and other intangible assets within the OIS and CCS segments [20] - The company completed a $550 million hybrid bond offering in Q2, enhancing financial flexibility [21] Q&A Session Summary Question: Overview of the broader dental market - Management indicated that patient volumes remain stable, but procedural utilization in elective areas like implants and ortho continues to be soft, with a focus on long-term strategies [31] Question: Distributor stock dynamics - Management noted no significant revenue impact from distributor stock changes, with healthy positions in imaging and CADCAM [34] Question: Motivation for joining Dentsply - The new CEO expressed interest in applying operational experience to enhance Dentsply's performance and accelerate growth [39] Question: Performance of implants - Management reported a decline in premium implants due to the transition from legacy brands, with expectations for growth driven by sales force changes and new consumer experiences [43] Question: Tariff assumptions - The annualized impact of tariffs has increased from $50 million to $80 million, with ongoing efforts to mitigate costs through supply chain efficiencies [48] Question: Adjustments on BiTE - A $4 million adjustment was noted for BiTE in Q2, with no further changes anticipated for the second half of the year [52] Question: Portfolio assessment - The CEO believes Dentsply is well-positioned in the market, with a focus on organic growth while remaining open to opportunistic acquisitions [58] Question: Market share dynamics in implants - Management acknowledged challenges in the value implant segment due to Middle East volatility but expects stronger performance in the second half of the year [90]
DENTSPLY SIRONA to Post Q2 Earnings: What's in Store for the Stock?
ZACKS· 2025-08-04 13:36
Core Insights - DENTSPLY SIRONA Inc. is set to release its second-quarter 2025 results on August 7, with expectations of revenue at $851.6 million and earnings at 29 cents per share [2][3] Group 1: Q2 Performance Expectations - The company has shown an average earnings surprise of 2.73% over the past four quarters, indicating a potential for positive performance [2] - The Imaging segment is expected to benefit from the relaunch of Orthophos SL and Primescan 2, which may have driven growth, particularly in Europe and APAC [4] - Orthodontics, particularly SureSmile, is anticipated to show stable global growth, although U.S. performance may be hindered by softer discretionary spending [5] Group 2: Challenges and Headwinds - The suspension of Byte aligner sales is projected to negatively impact organic sales by approximately two percentage points in 2025, affecting second-quarter results as well [6] - Essential Dental Solutions may have experienced stable patient traffic, but overall segment growth is likely to be limited by softness in elective procedures and weak U.S. implant sales [7] - Connected Technology Solutions, including CAD/CAM, continues to face macroeconomic pressures, with subdued retail demand in the U.S. despite growth in Germany [8] Group 3: Operational Insights - DENTSPLY SIRONA's Phase II transformation activities are on track to deliver full run-rate savings by the end of 2025, with expectations of gradual stabilization in gross margins throughout the year [9] - Cost initiatives and SKU rationalization may contribute to improved gross margins, aiding quarter-over-quarter growth in Q2 [11] Group 4: Earnings Prediction Model - The current model does not predict an earnings beat for DENTSPLY SIRONA, with an Earnings ESP of -0.99% and a Zacks Rank of 2 [12][13]
DENTSPLY SIRONA (XRAY) 2025 Conference Transcript
2025-05-28 14:45
Summary of Dentsply Sirona Conference Call Company Overview - Dentsply Sirona is a leading company in the dental market, with a global reach and significant international market presence [1] Key Financial Performance - Q1 2025 results exceeded guidance, with revenue down mid-single digits year-over-year primarily due to Byte [2][4] - EPS was well above guidance, indicating strong operational performance despite revenue challenges [2] Market Landscape - The overall dental market remains stable but has not returned to pre-COVID levels after five years [4][11] - Patient traffic is stable but still below pre-COVID levels, with slight degradation in customer sentiment noted [4][5] - Germany has shown decent performance and slight improvement in the last couple of quarters [7] Customer Sentiment and Behavior - Customer sentiment in the U.S. has shifted slightly from "not concerned" to "a little bit concerned," but this is more of a numerical shift than a significant change in behavior [5][9] - No significant changes in footfall or purchase intent reported by customers [10] Challenges in the Dental Market - Awareness around oral health and sensitivity to pricing are ongoing challenges affecting the dental market [12] - High interest rates have constrained capital equipment investments, particularly impacting the CTS (Capital Equipment) division [12][16] Division Performance and Growth Strategies - **CTS and Implants/Prosthetics**: Both divisions are expected to decline in 2025, accounting for nearly 50% of revenue. The company is focused on improving customer sentiment and investing in efficiency [14][16] - **DS Core Platform**: Significant investments have been made in the DS Core platform, with a 14% increase in users and a 25% increase in connected devices quarter-over-quarter [18][19] - **Implants**: The importance of the sales force in the implant community has been underestimated, and efforts are being made to improve sales rep training and customer engagement [20][21] - **Orthodontics**: Growth is expected to resume as the impact of the DSO loss is lapped, with double-digit growth reported in Europe for SureSmile [30][33] Margin and Expense Management - Despite negative revenue growth, all divisions reported year-over-year margin increases due to reduced expenditures and improved operational efficiency [35][36] - OpEx was down 14% year-over-year in Q1 2025, with expectations for continued reductions in the future [39][40] Future Outlook - The company aims to return to growth, with expectations for normalized growth in 2025 and acceleration into 2026 [42][44] - Continued focus on innovation and customer engagement is seen as critical for future success [44][46] Distributor Relationships - Ongoing discussions with key distributors, including Patterson, have deepened, with positive engagement noted [50][52] - The company is working to restore relationships with key distributors in Europe and the U.S. [51] Virtual Sales Force Initiative - A virtual sales force initiative has been launched, with approximately 100 reps making 2,000 calls daily and generating meaningful engagement with accounts [58][59] - The initiative aims to create demand independently of distributors and has already resulted in sales [64] Tariff Impact - The impact of U.S.-China tariffs on Dentsply Sirona is minimal, accounting for less than a couple of percentage points of revenue [67][68] - The company is taking proactive measures to mitigate potential tariff risks, including redistributing products to U.S. distribution sites [69][70]
DENTSPLY SIRONA(XRAY) - 2025 Q1 - Earnings Call Transcript
2025-05-08 13:32
Financial Data and Key Metrics Changes - In Q1, the company reported revenue of $879 million, representing a decline of 7.7% year-over-year, with organic sales down 4.4% due to a negative 4% BiTE impact [23][24] - Adjusted EPS for the quarter was $0.43, up 3.7% from the prior year, driven by higher adjusted EBITDA margins and a lower share count [25] - Adjusted EBITDA margins expanded by 220 basis points, benefiting from lower operating expenses and transformational savings [25] Business Line Data and Key Metrics Changes - Essential Dental Solutions segment saw organic sales increase by 0.4%, driven by growth in Europe and the rest of the world, despite lower volumes in the U.S. [27] - Orthodontic and Implant Solutions segment experienced a significant organic sales decline of 17.7%, primarily due to the loss of a DSO customer in the U.S. and lower lab volumes globally [28] - Connected Technology Solutions segment reported a slight organic sales decline of 0.5%, largely due to CADCAM declines in the U.S., although imaging performance showed growth across all regions [29] Market Data and Key Metrics Changes - U.S. organic sales declined by 14.9%, primarily impacted by a negative 9.8% from BiTE, while imaging growth was noted [31] - Europe saw organic sales increase by 1.1%, driven by strong performance in Germany, particularly in equipment and instruments [34] - Rest of World organic sales grew by 3.1%, with growth in imaging and WellSpec in China, offset by CADCAM declines [35] Company Strategy and Development Direction - The company is focused on driving reliable and sustainable performance, emphasizing customer-centric product innovation and operational efficiency [8][10] - The strategy includes enhancing the digital ecosystem through the DS Core platform, which has gained traction with over 42,000 unique users [14] - The company aims to improve customer engagement through revamped websites and a new e-commerce platform [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating global trade challenges and has developed plans to mitigate potential impacts from tariffs [7][12] - Despite a challenging macroeconomic environment, the company maintained its outlook for organic sales and adjusted EPS for 2025, while increasing reported sales expectations due to foreign currency translation changes [12][36] - Management noted stable patient volume and procedure utilization, although U.S. dentists expressed concerns about economic conditions affecting patient footfall [11] Other Important Information - The company is actively managing its balance sheet and has taken actions to strengthen its position, including entering into a bridge loan agreement [26] - The company has completed the closure of 10 manufacturing and distribution sites as part of its supply chain optimization efforts [23] Q&A Session Summary Question: Can you expand on the tariff impact? - Management indicated that tariffs have been factored into guidance, estimating an annualized impact of approximately $50 million, with about $0.10 impact on EPS [49][50] Question: Update on CFO search? - Management reported good progress in the CFO search, with candidates in the late phases of the process [52] Question: Insights on orthodontics and SureSmile? - Management acknowledged the need to reengage with the orthodontist community and improve user experience for SureSmile [58] Question: Clarification on EBIT margin? - Management noted that Q1 EBIT margin improvements are indicative of future performance, with a focus on judicious SG&A management [62] Question: Cash flow and CapEx expectations? - Management expects CapEx to decrease as ERP projects roll off, leading to improved free cash flow [108]
DENTSPLY SIRONA(XRAY) - 2025 Q1 - Earnings Call Transcript
2025-05-08 13:30
Financial Data and Key Metrics Changes - In Q1 2025, the company's revenue was $879 million, representing a decline of 7.7% year-over-year. Organic sales decreased by 4.4%, impacted by a negative 4% BiTE effect [23][24]. - Adjusted EBITDA margins expanded by 220 basis points, benefiting from lower operating expenses and transformational savings [25]. - Adjusted EPS for the quarter was $0.43, up 3.7% from the prior year, primarily due to higher adjusted EBITDA margins and a lower share count [25]. Business Line Data and Key Metrics Changes - Essential Dental Solutions segment saw organic sales increase by 0.4%, driven by growth in Europe and the rest of the world, despite lower volumes in the U.S. [26]. - Orthodontic and Implant Solutions segment experienced a significant organic sales decline of 17.7%, largely due to a negative BiTE impact and a loss of a DSO customer in the U.S. [27]. - Connected Technology Solutions segment had a slight organic sales decline of 0.5%, primarily due to CADCAM declines in the U.S., although imaging performance grew across all regions [28]. Market Data and Key Metrics Changes - U.S. organic sales declined by 14.9%, primarily due to a negative 9.8% impact from BiTE, while imaging growth was noted [30]. - Europe saw organic sales increase by 1.1%, driven by strong performance in Germany, which posted growth for the second consecutive quarter [33]. - The Rest of World segment experienced organic sales growth of 3.1%, with notable growth in imaging and WellSpec in China [34]. Company Strategy and Development Direction - The company is focused on driving reliable and sustainable performance, emphasizing customer-centric product innovation and operational efficiency [7][10]. - The strategy includes enhancing the digital ecosystem through the DS Core platform, which has gained traction with over 42,000 unique users [14]. - The company aims to improve customer engagement and experience through revamped websites and a new e-commerce platform [19][20]. Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by global trade situations and tariffs but expressed confidence in the company's ability to navigate these risks [6]. - The outlook for 2025 remains unchanged for organic sales and adjusted EPS, with reported sales revised to reflect foreign currency changes [12][35]. - Management noted stable patient volume and procedure utilization, despite some concerns among U.S. dentists regarding economic conditions [11]. Other Important Information - The company is actively managing its balance sheet and has taken steps to strengthen its position, including entering into a bridge loan agreement [25]. - The company has completed the closure of 10 manufacturing and distribution sites as part of its supply chain optimization efforts [23]. Q&A Session Summary Question: Can you expand on the tariff impact? - Management indicated that tariffs have been factored into guidance, estimating a $0.10 impact, with an annualized exposure of about $50 million [47][48]. Question: Update on the CFO search? - Progress is being made with several candidates in the late phases of the process [50]. Question: Insights on the orthodontics side? - Management noted the need to reengage with the orthodontist community and improve user experience with SureSmile [56]. Question: Context behind EBIT margin? - The improvement in Q1 EBIT margin is seen as a reasonable run rate for the rest of the year, with a focus on judicious SG&A management [62]. Question: Cash flow and CapEx expectations? - CapEx is expected to improve as ERP projects roll off, leading to better free cash flow [107].
DENTSPLY SIRONA(XRAY) - 2025 Q1 - Earnings Call Presentation
2025-05-08 11:17
First Quarter 2025 Earnings Conference Call May 8, 2025 Forward-Looking Statements and Associated Risks All statements in this Presentation that do not directly and exclusively relate to historical facts constitute "forward-looking statements." Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control, including those described in Part I, It ...
DENTSPLY SIRONA to Post Q1 Earnings: What's in Store for the Stock?
ZACKS· 2025-05-05 16:15
Core Viewpoint - DENTSPLY SIRONA Inc. is set to release its first-quarter 2025 results on May 8, with expectations of revenue at $851.6 million and earnings at 29 cents per share, following a trend of earnings misses in previous quarters [1][8]. Group 1: Financial Performance and Estimates - The Zacks Consensus Estimate for revenues in Q1 2025 is $851.6 million, while the earnings consensus is 29 cents per share [1]. - The company has experienced an average earnings surprise of -9.34% over the past four quarters, indicating challenges in meeting market expectations [1]. Group 2: Impact of Byte Business Wind-Down - The ongoing wind-down of the Byte business is a significant factor, having caused a $62 million year-over-year decline in sales in Q4 2024 and a non-cash goodwill impairment of $370 million [2]. - The strategic shift away from the direct-to-consumer aligner segment towards clinician-directed models like SureSmile is expected to influence revenue dynamics as the company aims to fully exit Byte by mid-2025 [2]. Group 3: Regional Sales Performance - The U.S. region reported a 29.9% decline in year-over-year sales in Q4 2024, attributed to Byte's exit, CAD/CAM segment underperformance, and unfavorable distributor ordering patterns [3]. - Investors are anticipated to monitor signs of stabilization or rebound in U.S. demand, particularly in procedural categories such as implants and endodontics [3]. Group 4: Growth in Key Segments - Despite overall revenue pressure, SureSmile and imaging categories showed resilience, with SureSmile growing over 20% in Europe and imaging increasing nearly 13% globally in Q4 2024 [4]. - The company is expected to maintain momentum in these higher-margin, tech-enabled product lines in Q1 2025 [4]. Group 5: Product Launches and Innovations - DENTSPLY SIRONA launched PrimeScan 2, an upgraded intraoral scanner, aimed at enhancing clinical experience and workflow integration [5]. - The European launch of the MIS LYNX implant system received positive feedback, and the rollout of the DS Core digital cloud platform is expected to support procedural growth in restorative and implant dentistry [6].
DENTSPLY SIRONA(XRAY) - 2024 Q4 - Earnings Call Transcript
2025-02-27 21:01
Financial Data and Key Metrics Changes - In Q4 2024, the company reported revenue of $905 million, representing a decline of 10.6% year-over-year and an organic sales decline of 10.7% [34][46] - Adjusted EPS for the quarter was $0.26, down 41.3% from the prior year due to lower margins and a higher tax rate [37][50] - The company generated $87 million of operating cash, down 45.6% year-over-year [38] Business Line Data and Key Metrics Changes - The Essential Dental Solutions segment saw organic sales decline by 3.4%, while the Orthodontic & Implant Solutions segment experienced a significant decline of 28.7% primarily due to the impact from Byte [39] - SureSmile grew low single digits globally, with over 20% growth in Europe [39] - The Connected Technology Solutions segment saw organic sales decline by 8.2% compared to the prior year quarter [40] Market Data and Key Metrics Changes - U.S. sales declined by 29.9%, largely driven by Byte and CAD/CAM impacts [42] - In Europe, organic sales increased by 1.8%, driven by growth in CTS, SureSmile, and Wellspect [43] - Rest of World organic sales declined by 2%, with EDS organic sales growing high single digits in China [44] Company Strategy and Development Direction - The company is exploring strategic alternatives for its Wellspect HealthCare business to unlock significant value for stakeholders [18][20] - A strategic decision was made to redeploy Byte resources to the SureSmile platform, focusing on enhancing direct-to-consumer demand and e-commerce [17] - The company aims to improve operational efficiencies and customer engagement through various foundational initiatives [21][60] Management's Comments on Operating Environment and Future Outlook - Management expects organic sales to decline by 2% to 4% in 2025, including a negative impact from Byte [51] - The external environment is anticipated to remain largely unchanged, with continued focus on innovation and clinical education as key value drivers [16][66] - Management expressed confidence in the company's ability to capitalize on its broad-based dental organization advantages [22] Other Important Information - The company recorded noncash charges for impairment of goodwill and other intangibles of approximately $370 million in Q4 [31] - The company completed the largest individual phase of its ERP deployment in the U.S. on November 1, 2024 [24] - The company plans to launch over 20 new products through 2026, enhancing its innovation pipeline [65] Q&A Session Summary Question: Can you talk about some of the new product areas that you're working on in Wellspect? - Management indicated that Wellspect and dental businesses are largely separated, allowing for strategic alternatives without significant overlap [76] Question: What gives you confidence in margin improvement throughout 2025? - Management stated that Q1 will be the lowest point of the year, with expectations for sequential improvement in margins as foundational initiatives ramp up [81] Question: Can you discuss the strategy for Byte and its implications for the P&L? - Management confirmed that Byte's capabilities will be redeployed to enhance the SureSmile platform, with expectations of a substantial headwind to growth in 2025 [94][101] Question: What is the current status of the U.S. implant team and its growth prospects? - Management acknowledged disappointing growth in the U.S. implant team but emphasized ongoing efforts to enhance digital connectivity and customer education [105][108] Question: Can you provide an update on the German tax situation? - Management stated there is no meaningful update at this time, continuing to work with authorities [131]